Suscribirse

Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma - 09/09/11

Doi : 10.1016/S0091-6749(98)70086-7 
B.Lauren Charous, MD, Elkan F. Halpern, PhD, Gary C. Steven, MD, PhD
Milwaukee, Wis 

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Background Although antiinflammatory therapy is accepted as the cornerstone of asthma treatment, available systemic immunosuppressive agents are not widely used because of justified concerns over potential toxicity. Hydroxychloroquine (HCQ) is a well-tolerated, safe immunomodulating drug, with proven efficacy in rheumatic diseases and known actions that suggest potential utility in the treatment of asthma. Objective: We sought to assess the effectiveness of HCQ in subjects with moderate symptomatic asthma. Methods: Symptomatic asthmatic subjects receiving stable doses of at least 6 puffs of inhaled corticosteroid per day with daily need for β2-adrenergic agonists were studied. After baseline run-in, these subjects were randomized to 30 weeks of HCQ (n = 8) or placebo (n = 9). Objective measures included change from baseline mean FEV1, morning and evening peak flows, β2-agonist use, IgE level, and need for rescue cortico-steroids. Subjective symptom scores from bidaily diaries were also obtained. Results: In the treatment group, mean FEV1 at the last 2 visits on therapy increased by 10.8% (P < .05), morning peak flows rose 16.2% (P < .03), evening peak flows rose 14.2% (P < .04), and β2-agonist use fell 18.6% (P < .03). Mean IgE level declined 48% from 240 to 125 IU/mL (P < .05). In the placebo group no significant change in these parameters occurred. Comparison of changes in these objective measures between the treatment and placebo groups failed to reach significance in the small population studied. Corticosteroid rescue interventions were required in 4 patients receiving placebo and 2 receiving HCQ. HCQ was well tolerated without notable side effects. Conclusions: Although the size of our sample population precludes definitive conclusions, these findings extend previous open-label observations. The late improvement in the HCQ group is consistent with its known slow onset of action. Further studies are warranted to confirm the antiasthmatic and antiallergic effects of HCQ and to investigate its potential as a disease-modifying agent. (J Allergy Clin Immunol 1998;102:198-203).

El texto completo de este artículo está disponible en PDF.

Keywords : Asthma, IgE, hydroxychloroquine, antiinflammatory agents, asthma therapy, antimalarial

Abbreviations : HCQ:, PEFR:


Esquema


 From the Allergy and Respiratory Care Center, Milwaukee Medical Clinic, Milwaukee.
 Supported by Sanoff Winthrop, Heathscan, and the Milwaukee Medical Clinic.
 Reprint requests: B. Lauren Charous, MD, Allergy and Respiratory Care Center, Milwaukee Medical Clinic, 3003 W. Good Hope Road, Milwaukee, WI 53217.
 0091-6749/98 $5.00 + 0  1/1/91950


© 1998  Mosby, Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 102 - N° 2

P. 198-203 - août 1998 Regresar al número
Artículo precedente Artículo precedente
  • Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis
  • Ramón Vargas, Robert J. Dockhorn, Steven R. Findlay, Phillip E. Korenblat, Elizabeth A. Field, Kenneth M. Kral
| Artículo siguiente Artículo siguiente
  • Extrathoracic airway dysfunction in cough associated with gastroesophageal reflux
  • Giovanni Rolla, Paola Colagrande, Mauro Magnano, Valeria Debernardi, Luca Dutto, Luca Delpiano, Paola Cassolino, Caterina Bucca

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.